OPK Opko Health Inc

●

ModeX advanced its antiviral and immune-oncology product pipeline. ModeX advanced its pipeline of antiviral and immune-oncology programs utilizing its next-generation multispecific antibodies, with expectations for one oncology program to enter the clinic this year. In 2023, Modex secured two collaborations including one with Merck to develop MDX-2201, its vaccine for Epstein-Barr virus, and another with BARDA to develop novel multispecific antibodies against viral infectious disease threats.

●

NGENLA® has now been approved in over 50 countries including the U.S., Japan, EU Member States, Canada and Australia. Pfizer, OPKO’s commercial partner, has launched NGENLA in all priority global markets. OPKO is entitled to gross profit sharing in all global markets based on sales of both NGENLA and Genotropin. NGENLA is the first once-weekly product approved for the treatment of pediatric growth hormone deficiency in Japan, Canada, Australia, the United Kingdom, Taiwan, the United Arab Emirates and Brazil.

●

BioReference Health continued implementing its REACH program to improve operating efficiencies and enhance productivity. With the goal of achieving profitability this year, BioReference continued to implement initiatives to reduce costs and improve productivity by enhancing innovation of its higher-value specialty testing segments. Other efforts to return this business to profitability include expanding into new markets and marketing to new customer segments, such as pharmaceutical companies.

●

Approvals received for OPKO Health-branded Storefront on Alibaba’s Tmall Global Platform in China. NextPlat Corp., a global e-Commerce provider, is launching an OPKO Health-branded online storefront on Alibaba's Tmall Global e-commerce platform in China. This new online storefront will initially list up to 40 OPKO health and wellness products featuring an assortment of nutraceuticals for bone, joint and eye health, as well as supplements for nutrition and immunity defense. NextPlat intends to significantly expand the OPKO online storefront with a wide array of veterinary and animal health products, subject to final Chinese regulatory approval, which is expected during the second quarter of 2024.

●

Pharmaceuticals: Revenue from products in the fourth quarter of 2023 increased to $43.0 million from $37.9 million in the fourth quarter of 2022, driven by growing sales from our international operations, positively impacted by foreign currency fluctuations of approximately $1.3 million. Furthermore, sales of RAYALDEE increased to $9.3 million from $9.1 million in the prior-year period. Revenue from the transfer of intellectual property was $14.7 million in the fourth quarter of 2023 compared with $8.1 million in the 2022 period, which included revenue of $12.2 million and $3.0 million, respectively, of gross profit share payments for NGENLA; the fourth quarter of 2023 included a catch-up payment of $3.1 million for the U.S. for the third quarter of 2023. Total costs and expenses were $73.8 million in the fourth quarter of 2023 compared with $68.0 million in the prior-year period. The increase was primarily from higher cost of product revenues reflecting sales growth from OPKO’s international operating companies, negatively impacted by unfavorable foreign currency fluctuations of $1.1 million. Furthermore, research and development expenses increased as we continued to invest in our pipeline of immune-oncology and infectious disease programs. Operating loss was $16.0 million in the fourth quarter of 2023 compared with $22.0 million in the fourth quarter of 2022.

●

Diagnostics: Revenue from services in the fourth quarter of 2023 was $124.2 million compared with $139.4 million in the prior-year period. The decrease reflects lower clinical test reimbursement of $9.0 million due to the mix of testing ordered, partially offset by an increase of $0.9 million from higher clinical test volume. COVID-19 testing volume and reimbursement decreased by $7.1 million due to higher utilization of antigen point-of-care diagnostic tests, as well as a shift in customer mix. Total costs and expenses for the fourth quarter of 2023 were $166.4 million compared with $162.5 million in the fourth quarter of 2022. This increase is primarily due to non-recurring employee retention and severance costs associated with our ongoing REACH initiatives. Through these initiatives, the Company has reduced ongoing expenses on an annualized basis by $10.1 million. Operating loss in the fourth quarter of 2023 was $42.3 million, including $4.7 million of non-recurring expenses and $5.4 million of revenue adjustments, compared with an operating loss of $23.1 million in the 2022 period.

●

Consolidated: Consolidated total revenues for the fourth quarter of 2023 were $181.9 million compared with $185.4 million for the comparable 2022 period. Operating loss for the fourth quarter of 2023 was $69.1 million compared with an operating loss of $55.3 million for the 2022 quarter. Net loss for the fourth quarter of 2023 was $65.5 million, or $0.09 per share, compared with a net loss of $85.2 million, or $0.11 per share, for the 2022 quarter. Net loss for the 2023 period included a mark-to-market adjustment of $3.2 million compared with $49.1 million in the 2022 period related to the decrease in the share price of GeneDx. In addition, OPKO reported an income tax benefit in the 2023 period of $6.0 million compared with $17.0 million in the 2022 period.

●

Cash and cash equivalents: Cash and cash equivalents were $95.9 million as of December 31, 2023. Subsequent to the close of the fourth quarter, OPKO completed the sale of $230 million aggregate principal amount of 3.75% Convertible Senior Notes due 2029 and exchanged approximately $144.4 million of the Company’s outstanding 4.50% Convertible Senior Notes due 2025. The Company used approximately $50.0 million of the net proceeds to repurchase shares of the Company’s common stock from purchasers of the notes. Additionally, OPKO issued and sold approximately $71.1 million aggregate principal amount of its 3.75% Convertible Senior Notes due 2029 to several holders, including Company affiliates in exchange for the outstanding 5% Convertible Promissory Notes and accrued interest.

As of

December 31,

2023

December 31,

2022

Assets:

Cash and cash equivalents

$

95.9

$

153.2

Other current assets

213.6

241.3

Total current assets

309.5

394.5

In-process research and development and goodwill

793.3

790.9

Other assets

908.9

981.9

Total Assets

$

2,011.7

$

2,167.3

Liabilities and Equity:

Accounts payable

$

69.7

$

67.0

Accrued expenses

90.1

98.3

Current portion of convertible notes

0.0

3.1

Other current liabilities

40.3

45.1

Total current liabilities

200.1

213.5

Long-term portion of convertible notes

214.3

210.4

Deferred tax liabilities, net

126.8

126.4

Other long-term liabilities, principally contract liabilities,

leases, contingent consideration, and lines of credit

81.3

55.4

Total Liabilities

622.5

605.7

Equity

1,389.2

1,561.6

Total Liabilities and Equity

$

2,011.7

$

2,167.3

For the three months ended

December 31,

For the twelve months ended

December 31,

2023

2022

2023

2022

Revenues

Revenue from services

$

124.2

$

139.4

$

515.3

$

755.6

Revenue from products

43.0

37.9

167.5

142.9

Revenue from transfer of intellectual property and other

14.7

8.1

180.7

105.7

Total revenues

181.9

185.4

863.5

1,004.2

Costs and expenses

Cost of service revenues

112.4

106.4

445.8

627.6

Cost of product revenues

24.8

23.0

99.5

88.4

Selling, general, and administrative

72.9

74.0

300.6

372.7

Research and development

19.4

19.5

89.6

73.9

Contingent consideration

(0.0

)

(0.6

)

(1.0

)

(1.3

)

Amortization of intangible assets

21.5

21.6

86.0

87.8

Gain on sale of assets

0.0

(3.2

)

0.0

(18.6

)

Total costs and expenses

251.0

240.7

1,020.5

1,230.5

Operating loss

(69.1

)

(55.3

)

(157.0

)

(226.3

)

Other expense, net

(3.4

)

     (46.9

)

(27.4

)

(165.2

)

Loss before income taxes and investment losses

(72.5

)

(102.2

)

(184.4

)

(391.5

)

Income tax benefit (provision)

6.0

17.0

(4.4

)

63.5

Loss before investment losses

(66.5

)

(85.2

)

(188.8

)

(328.0

)

Loss from investments in investees

(0.0

)

(0.0

)

(0.1

)

(0.4

)

Net loss

$

(65.5

)

$

(85.2

)

$

(188.9

)

$

(328.4

)

Loss per share,

basic and diluted

$

(0.09

)

$

(0.11

)

$

(0.25

)

$

(0.46

)

Weighted average common shares outstanding, basic and diluted

751,506,257

750,169,485

 751,716,915

719,060,942